The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics

David C. Wheeler, Bergur V. Stefansson, Mikhail Batiushin, Oleksandr Bilchenko, David Z.I. Cherney, Glenn M. Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits-Filho, Hans Furuland, José Luis Górriz, Tom Greene, Hermann Haller, Fan Fan Hou, Shin Wook Kang, Rey Isidto, Dinesh Khullar, Patrick B. Mark, John J.V. McMurrayNaoki Kashihara, Michal Nowicki, Frederik Persson, Ricardo Correa-Rotter, Peter Rossing, Robert D. Toto, Kausik Umanath, Pham van Bui, István Wittmann, Magnus Lindberg, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint Dive into the research topics of 'The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics'. Together they form a unique fingerprint.

Medicine & Life Sciences